Steven Pipe, MD, NHF's Chair of MASAC, looks at the future of bleeding disorders treatment.
Barry Haarde was a cyclist and community activist whose strength will never be forgotten.
The study focused on individuals who were previously treated prophylactically with a standard half-life (SHL) factor product, then switched to prophylaxis with an EHL therapy.
The goal of the workshop is to solicit hemophilia community-wide input into a coordinated national blueprint for future basic, translational, and clinical research.
The medication is indicated for on-demand treatment and control of bleeding episodes.
This webinar is free and open to public health professionals, clinicians, and researchers who want more information about hemophilia.
NIH will recognize Rare Disease Day with speakers, panel discussions and more on March 1, 2018.
Plan for the unexpected with these emergency preparendness resources.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car